Intravenous Dexmedetomidine 0.75 mcg/kg May Optimize Analgesia After Femoral Block
A propensity-matched retrospective cohort suggests an intermediate 0.75 mcg/kg intravenous dexmedetomidine dose matches the analgesic benefit of 1 mcg/kg while carrying numerically less bradycardia in anterior cruciate ligament reconstruction.
DEX prolongs analgesia in ACL reconstruction at safer doses.
Optimizing analgesic protocols in anterior cruciate ligament (ACL) reconstruction can enhance postoperative recovery and safety. Intravenous dexmedetomidine (DEX) doses of 0.75 μg/kg and 1 μg/kg extended analgesia duration compared to ropivacaine alone, with a plateau observed at 0.75 μg/kg. The findings suggest DEX at 0.75 μg/kg offers effective analgesia with fewer safety concerns, but the study's retrospective nature limits causality. Prospective trials are needed. DEX at 0.75 μg/kg optimizes analgesia duration in ACL reconstruction, minimizing safety risks.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Zhai W, Yu Z, Qu Y, et al. Intravenous dexmedetomidine dose and analgesic outcomes after femoral nerve block for anterior cruciate ligament reconstruction: a single-centre retrospective cohort study in China. BMJ open. 2026;16(8):e121130. doi:10.1136/bmjopen-2026-121130
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.